Uniqure NV Huntingtons Disease Program Update Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Huntingtons Disease Program Update AMT-130. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to turn the conference over to Maria Cantor, Chief Corporate Affairs Officer. Please go ahead.
Good morning, and thank you for joining us. This morning due to our announced updated interim data on ANT-130 therapy in patients with Huntington's disease from our ongoing Phase I/ll clinical trial in the United States and Europe. This update includes data on safety and tolerability, exploratory efficacy, biomarkers, and volumetric imaging, including up to 30 months of follow-up on patients treated with AMT-130 in a low-dose cohort and up to 24 months of follow-up, treated with AMT-130 in a high-dose cohort.
Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer, Dr. Walid Abi-Saab, our Chief Medical Officer, and Dr. Ed Wild, Professor of Neurology
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |